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Designed cell penetrating peptide dendrimers
eﬃciently internalize cargo into cells†
Gabriela A. Eggimann,‡ Emilyne Blattes,‡ Stefanie Buschor, Rasomoy Biswas,
Stephan M. Kammer, Tamis Darbre* and Jean-Louis Reymond*
Redesigning linear cell penetrating peptides (CPPs) into amulti-branched
topology with short dipeptide branches gave cell penetrating peptide
dendrimers (CPPDs) with higher cell penetration, lower toxicity and
hemolysis and higher serum stability than linear CPPs. Their use is
demonstrated by delivering a cytotoxic peptide and paclitaxel into cells.
The cell membrane poses an impermeable barrier for a large
number of compounds, in particular peptides, limiting their use
as drugs. Nevertheless the discovery of the cell penetrating properties
of the HIV-1 Tat protein1 led to the discovery of a variety of cell
penetrating peptides (CPPs),2 an eﬀect which was later also reported
for synthetic oligomer analogs of linear peptides,3 cyclic peptides,4
and various organic dendrimers.5 CPPs can serve as carriers for drug
delivery, however they suﬀer from the typical metabolic instability of
linear peptides and tend to be hemolytic and cytotoxic. Interestingly
the cell internalization of CPPs can be enhanced by grafting them
onto multivalent scaﬀolds, but their toxicity is usually also increased
in such constructs despite the fact that their folding propensity is
retained.6 We showed recently that peptide dendrimers containing
very short mono- or dipeptide branches,7 while not able to form
stable secondary structures,7b are generally more resistant to
proteolytic degradation compared to linear peptides,7c and show
almost no cytotoxicity when used for DNA transfection7f and only
very weak hemolysis when designed as antimicrobials,7e which is
probably a benefit of their particular molten globule conformation
enforced by the dendritic topology.7a Although no increase in cellular
uptake was reported with branched octaarginines compared to linear
(Arg)8,
8 we asked the question whether a broader survey of CPPs
redesigned in a multi-branched topology might lead to cell
penetrating peptide dendrimers (CPPDs) with higher cellular
uptake, metabolic stability and lower toxicity compared to linear
CPPs, and potential use as drug delivery agents.
Fourteen peptide dendrimers were prepared by SPPS with
sequence (X8X7)8(KX
6X5)4(KX
4X3)2KX
2X1K* (K = branching lysine) and
labeled with 5(6)-carboxyfluorescein (CF) attached to the e-amino
group of the core lysine residue (K*) (Scheme 1). Variable residues
(X) were assigned to amino acids found in the linear cationic CPP Tat1
or the amphipathic CPPs TP109 and pVEC10 to form dendrimers with
Arg and Lys (D1–D4 and D11) or only Lys (D5–D10) as cationic
Scheme 1 Synthesis of CPPD. Conditions: (a) Fmoc solid-phase peptide
synthesis (SPPS), Xi = amino acid, K = branching lysine; (b) PhSiH3, Pd(PPh3)4;
(c) 5(6)-carboxyfluorescein, HOBt, DIC; (d) piperidine/DMF; (e) optional:
Ac2O; (f) CF3CO2H/iPr3SiH/H2O, then preparative HPLC; (g) ClCH2CO-
GG[KLAKLAK]2NH2, DIEA; (h) PTX-PDP, DIEA. See ESI† for details.
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residues, featuring various ratios and distribution of cationic and
hydrophobic side chains in the branches and optional acetylation of
N-termini to reduce the number of positive charges (Table 1).
CD spectra of CPPDs show random coil signals independent of
amino acid composition consistent with the disordered conformation
of branched peptides and similar to Tat and pVEC (Fig. 1a and
Fig. S1, ESI†). CPPD uptake by HeLa, CHO and Jurkat cells was
evaluated by flow cytometry after 1 h incubation of the cells with 1 mM
or 10 mM compounds (Table 1, Fig. 1b–d and Fig. S2, ESI†). A strong
fluorescence increase was observed with arginine containing
Table 1 Synthesis and cellular uptake of CF-labelled CPPs and CPPDs
Cpd. Sequencea Yieldb (mg (%)) +c Arg Lys Hyd.d
MFI av. (1 mM) (10 mM)e
Hemolysis f
(mg mL1/mM)HeLa, CHO, Jurkat
Tat *-YGRKKRRQRRR 90.9 (26) 8 6 2 1 2, 2, 11 14, 23, 65 125/44
D1 (RL)8(KRL)4(KKK)2KGYK* 14.7 (3) 24 12 4 13 11, 10, 49 214, 114, 1450 31/4
D2 (RL)8(KLL)4(KKK)2KGYK* 9.6 (6) 20 8 4 17 20, 22, 108 158, 175, 631 31/4
D3 (RL)8(KNN)4(KKK)2KGYK* 23.3 (5) 20 8 4 9 5, 4, 40 64, 48, 210 125/17
D4 (GY)8(KKR)4(KQQ)2KRRK* 13.2 (2) 18 6 4 12 3, 4, 27 19, 51, 112 63/9
AcD4 (AcGY)8(KKR)4(KQQ)2KRRK* 4.7 (1) 10 6 4 12 3, 2, 9 15, 25, 65 250/38
TP10 *-AGYLLGKINLKALAALAKKIL 51.3 (15) 4 — 4 15 7, 6, 23 152, 186, 385 31/10
D5 (AL)8(KIK)4(KLA)2KKIK* 33.4 (5) 13 — 5 25 4, 9, 28 46, 122, 118 63/11
D6 (LA)8(KKL)4(KKL)2KYAK* 55.1 (8) 14 — 6 24 2, 5, 7 17, 21, 31 1000/163
AcD6 (AcLA)8(KKL)4(KKL)2KYAK* 9.0 (7) 6 — 6 24 2, 7, 14 35, 40, 64 n.d.
D7 (IK)8(KLA)4(KLA)2KKIK* 6.4 (1) 17 — 9 21 5, 14, 29 33, 51, 355 125/19
AcD7 (AcIK)8(KLA)4(KLA)2KKIK* 3.0 (1) 9 — 9 21 5, 14, 190 33, 259, 862 63/10
D8 (LA)8(KIK)4(KLA)2KKIK* 11.1 (2) 13 — 5 25 2, 4, 11 20, 30, 71 63/11
D9 (LA)8(KLA)4(KIK)2KKIK* 8.2 (2) 11 — 3 27 2, 2, 10 14, 14, 61 125/22
D10 (LA)8(KLA)4(KLA)2KKIK* 12.3 (3) 9 — 1 29 3, 2, 5 9, 8, 36 250/48
pVEC *-LLIILRRRIRKQAHAHSK 94.3 (26) 6 4 2 8 36, 71, 84 126, 210, 292 4/1
D11 (LI)8(KRK)4(KRA)2KHSK* 15.0 (2) 18 6 4 18 3, 12, 58 60, 106, 968 500/70
AcD11 (AcLI)8(KRK)4(KRA)2KHSK* 7.0 (5) 10 6 4 18 4, 8, 26 44, 105, 385 n.d.
a One letter codes for amino acids. Branching diamino acids are shown in italics. * = 5(6)-carboxyfluorescein amidated to the Lys side chain (K*) or
the N-terminus (*-) added as the last coupling step, see ESI for details. Ac = acetyl. All peptides are carboxamide (CONH2) at the C-terminus.
b Yields
given for RP-HPLC purified products as TFA salts. c + = number of cationic amino acid side chains (Lys and Arg) and free N-termini. d Hyd =
hydrophobic residues: Ala, Ile, Leu and Tyr. e Flow cytometry data. MFI average = average of the mean fluorescence intensity of the tested peptides
over background. Three independent experiments are used to get values. f Hemolysis assay detailed in ESI. n.d. = not determined.
Fig. 1 (a) CDmeasurements ofD1 (blue),D5 (green),D10 (grey), andD11 (red). Tat (black), TP10 (dotted black) in PBS buﬀer (pH 7.4). (b–d) Flowcytometry histograms
for HeLa (b), CHO (c) and Jurkat (d) cells after 1 h incubationwith 10 mMof peptide dendrimers at 37 1C.D1 (blue),D5 (green),D10 (black), andD11 (red). Untreated cells
(grey), Tat (filled blue), TP10 (filled green). (e) Observed uptake of D1 (10 mM) after 1 h incubation at 37 1C on HeLa cells in live confocal microscopy of the differential
interference contrast (DIC, right panel) and the CF fluorescence at 525 nm (middle panel). The left panel shows the merged images of the DIC and fluorescence
pictures. White bar = 20 mm. See Fig. S5 (ESI†) for data with CPPD D11. (f) Uptake levels of D1 and D11 in HeLa cells in the presence of various inhibitors. Cells were
pretreated 30minwith 50 mMchlorpromazine (CPZ), 20 mM rottlerin (Rot), 25 mgmL1 nystatin (Nys) or cooled down at 4 1Cprior to 1 h incubationwith 10 mMCPPDor
linear octaarginine (R8) in the presence of an inhibitor. Error bars represent the SD of three independent experiments. See also Fig. S6 (ESI†) for CHO cells.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
M
ay
 2
01
4.
 D
ow
nl
oa
de
d 
on
 0
8/
12
/2
01
4 
13
:5
3:
58
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
7256 | Chem. Commun., 2014, 50, 7254--7257 This journal is©The Royal Society of Chemistry 2014
dendrimers D1 and D2 (staining 10–15 times higher than the parent
linear Tat), D11 and AcD11 (staining comparable to the parent linear
pVEC). Exchanging the eight leucines in the G2-branches of D2 for
polar asparagines to form D3 decreased the MFI average in spite of
the same total number of cationic residues (8 Arg and 4 Lys),
highlighting the importance of hydrophobic residues for uptake. D5
and AcD7 with only lysine as a cationic residue also showed strong
fluorescence comparable to the parent linear TP10, implying that
arginine is not necessary for cellular uptake of CPPD. The remaining
CPPDs showed MFI average comparable to linear Tat. Hydrophobic
D10 with only one cationic side chain was the least efficient CPPD in
the library.
Fixed confocal microscopy images with HeLa and CHO cells
confirmed the trends seen in flow cytometry and revealed the cellular
localization of peptide dendrimers (Fig. S3, ESI†). For the Arg
containing dendrimers D1, D2, D3 and D11, and D5 with only Lys
as a cationic residue, images showed a strong staining of the
cytoplasm similar to Tat in both cell lines. In contrast to PAMAM
dendrimers,5b acetylation of N-terminal amino groups did not
block cellular uptake of CPPDs, although diﬀerences of subcellular
localization were visible between D11 (homogeneous staining) and
AcD11 (punctuated patterns). Live confocal microscopy experiments
were performed with D1 and D11 to confirm cellular uptake and
distribution (Fig. 1e, Fig. S5 and S6, ESI†). After 1 h, dendrimers were
found inside cells localized in the cytoplasm in a punctuated pattern
suggesting confinement in endosomes.
Both energy-dependent endocytosis and energy-independent
or direct translocation across the cell membrane have been
proposed as uptake mechanisms for linear CPPs.11 The uptake
of dendrimer D1 by HeLa cells was reduced by chlorpromazine,
indicating clathrin dependent uptake, and to a lesser extent by
rottlerin (macropinocytosis inhibitor) and nystatin (caveola/lipid
raft-dependent endocytosis inhibitor) (Fig. 1f). Uptake was only
30% lower at 4 1C compared to that at 37 1C, suggesting that
direct membrane translocation also takes place for D1. Dendrimer
D11 showed a similar pattern however with reduced uptake at 4 1C,
indicating lower self-translocating ability probably due to its smaller
number of positive charges and diﬀerent distribution of Arg residues
in the branches compared to D1. Results with CHO cells (Fig. S6,
ESI†) show primarily a clathrin dependent uptake for both D1 and
D11 and a reduced uptake at 4 1C (energy-dependent uptake mostly)
in line with previous observations that the cell type plays a critical
role in the internalizationmechanism of CPPs. In the case of CPPDs,
clathrin mediated uptake appears to be the major process of
internalization taking place in both cell lines.
CPPDs were not significantly toxic to HeLa or CHO cells (up
to 10 mM, 24 h, Fig. S4, ESI†). However less than 50% viable
Jurkat cells remained after 24 h exposure to 10 mM pVEC, D1, D2,
D7, D11 or AcD11, which belong to the most cell penetrating
compounds. While hemolysis was very strong for the linear CPP
pVEC (4 mg mL1), CPPDs were less hemolytic including those with
strong cell penetrating properties (30–500 mg mL1, Table 1).
Dendrimers D1 and D11 combined eﬃcient uptake into cells
with moderate toxicity and were further investigated. Degradation
experiments in human serum showed that 40% of D1 and D11
were still unchanged after 12 h while linear Tat was completely
degraded, in line with previous reports that peptide dendrimers
are more resistant to proteolysis than linear peptides (Fig. S7,
ESI†).7d–f To evaluate the ability of D1 and D11 to deliver cargos
into cells, dendrimers were conjugated via a thioether bridge to
the a-helical tetradecapeptide [KLAKLAK]2 (KLA), an antimicrobial
peptide that does not penetrate mammalian cells but induces cell
death by disrupting themitochondrial membrane if delivered into
the cytosol.12 The resulting conjugates D1-KLA and D11-KLA
(Scheme 1) were found to be significantly more cytotoxic to HeLa
and CHO cells compared to Tat-KLA at 10 mM (Fig. S8 and S9,
ESI†), while KLA alone or an ungrafted dendrimer were not toxic
(Table 2, Fig. S10, ESI†). Covalent conjugation to CPPD does not
change the bioactivity of KLA since disulfide bridged conjugates
to both D1 and D11 showed cytotoxicity similar to the thioether
adducts (Fig. S11, Table S1, ESI†).
In a further example,D1 andD11 were conjugated to paclitaxel
(PTX), a notoriously insoluble anticancer drug whose solubility
and targeting can be significantly improved by incorporation into
a variety of nanocarriers including dendrimers and peptides.13
CPPD conjugatesD1-PTX andD11-PTX were prepared by disulfide
bond formation between D1-Cys or D11-Cys and paclitaxel-20-(3-
(2-pyridyldithio)) propionate (PTX-PDP, Scheme 1). The dithiopro-
pionyl linker has been reported for PTX-octaarginine14 and for
dendrimer drug conjugates15 and is susceptible to intracellular
reductive cleavage. Our CPPD-PTX conjugates were water soluble
and stable in cell culture over the time of the experiment, yet
retainedmost of the selective cytotoxicity of PTX to HeLa cells over
CHO cells (Table 2, Fig. S12, ESI†).
In summary, redesigning CPPs into G3 peptide dendrimers
with short dipeptide branches gave CPPDs with stronger cellular
uptake, lower cytotoxicity and hemolysis, and higher stability
towards serum degradation compared to their linear counterpart.
Cellular uptake was observed in a diversity of sequences containing
either Arg or Lys as a cationic residue and a balanced ratio of
hydrophobic residues. Dendrimer D1 inspired by the Tat peptide
andD11 inspired by pVEC eﬃciently localized in the cytoplasm and
delivered cytotoxic cargo into cells. The low intrinsic toxicity and
hemolysis of CPPDs might result from their inability to fold into
amphipathic a-helical membrane lytic aggregates. The higher
cellular uptake of CPPDs compared to linear CPPs probably reflects
in part their larger size, which is remarkably obtained without
increased synthetic complexity since the described CPPDs are
Table 2 Cytotoxicity of CPPD-drug conjugatesa
Cpd. IC50 HeLa cells IC50 CHO cells
KLA c20 mM (100%)b c20 mM (93%)b
D1-KLA 4.6  0.2 mM 7.8  0.6 mM
D11-KLA 6.0  0.3 mM 8.9  0.6 mM
Tat-KLA 10.1  0.5 mM B20 mM (48%)b
Paclitaxel (PTX) 8.4  0.6 nMc B4 mM (60%)b
D1-PTX 47  15 nM B4 mM (57%)b
D11-PTX 41  9 nM B4 mM (46%)b
a Cell survival measured after 24 h (KLA series) or 72 h (paclitaxel series)
with the WST-8 assay. b % of surviving cells at the indicated concen-
tration, which was the highest measured. No IC50 is given when the full
inhibition curve could not be measured. c With 1.6% DMSO added to
solubilise paclitaxel.
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obtained in only 12 SPPS coupling steps warranting low pro-
duction costs. Due to their ease of synthesis and favorable
properties CPPDs represent a promising and versatile new class
of cell penetrating devices.
This work was supported financially by the University of
Berne and the Swiss National Science Foundation.
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